Latest Octagon Capital Advisors LP Stock Portfolio
Octagon Capital Advisors LP Performance:
2024 Q3: -6.17%YTD: -13.47%2023: 6.15%
Performance for 2024 Q3 is -6.17%, and YTD is -13.47%, and 2023 is 6.15%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $642.9 Millions as of 30 Sep, 2024.
The top stock holdings of Octagon Capital Advisors LP are APLS, VRNA, . The fund has invested 13.5% of it's portfolio in APELLIS PHARMACEUTICALS INC and 8.2% of portfolio in VERONA PHARMA PLC.
The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), AN2 THERAPEUTICS INC (ANTX) and AKERO THERAPEUTICS INC (AKRO) stocks. They significantly reduced their stock positions in DYNE THERAPEUTICS INC (DYN), PRAXIS PRECISION MEDICINES I (PRAX) and CENTURY THERAPEUTICS INC (IPSC). Octagon Capital Advisors LP opened new stock positions in COGENT BIOSCIENCES INC (COGT), PHARVARIS N V (PHVS) and CYBIN INC (CYBN). The fund showed a lot of confidence in some stocks as they added substantially to NUVATION BIO INC (NUVB), CORBUS PHARMACEUTICALS HLDGS (CRBP) and VIRIDIAN THERAPEUTICS INC (VRDN).
The top stock holdings of Octagon Capital Advisors LP are APLS, VRNA, . The fund has invested 13.5% of it's portfolio in APELLIS PHARMACEUTICALS INC and 8.2% of portfolio in VERONA PHARMA PLC.
The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), AN2 THERAPEUTICS INC (ANTX) and AKERO THERAPEUTICS INC (AKRO) stocks. They significantly reduced their stock positions in DYNE THERAPEUTICS INC (DYN), PRAXIS PRECISION MEDICINES I (PRAX) and CENTURY THERAPEUTICS INC (IPSC). Octagon Capital Advisors LP opened new stock positions in COGENT BIOSCIENCES INC (COGT), PHARVARIS N V (PHVS) and CYBIN INC (CYBN). The fund showed a lot of confidence in some stocks as they added substantially to NUVATION BIO INC (NUVB), CORBUS PHARMACEUTICALS HLDGS (CRBP) and VIRIDIAN THERAPEUTICS INC (VRDN).
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of -6.17% in the last quarter. In trailing 12 months, it's portfolio return was 6.92%.
New Buys
| Ticker | $ Bought |
|---|---|
| cogent biosciences inc | 14,094,000 |
| pharvaris n v | 11,491,100 |
| cybin inc | 4,352,510 |
| unicycive therapeutics inc | 3,491,220 |
| black diamond therapeutics i | 2,583,900 |
| nuvation bio inc | 715,249 |
| neurogene inc | 629,400 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| nuvation bio inc | 2,720 |
| corbus pharmaceuticals hldgs | 128 |
| viridian therapeutics inc | 40.32 |
| mind medicine mindmed inc | 40.18 |
| allovir inc | 14.31 |
| arrivent biopharma inc | 9.6 |
| structure therapeutics inc | 5.08 |
| apellis pharmaceuticals inc | 4.38 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| dyne therapeutics inc | -77.75 |
| century therapeutics inc | -50.00 |
| nkarta inc | -50.00 |
| praxis precision medicines i | -50.00 |
| insmed inc | -32.82 |
| bridgebio pharma inc | -20.00 |
| centessa pharmaceuticals plc | -14.2 |
| perspective therapeutics inc | -10.00 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cybin inc | -5,041,860 |
| an2 therapeutics inc | -6,923,560 |
| terns pharmaceuticals inc | -9,291,560 |
| adicet bio inc | -929,037 |
| elevation oncology inc | -2,016,900 |
| poseida therapeutics inc | -2,149,120 |
| fate therapeutics inc | -1,708,220 |
| jasper therapeutics inc | -6,526,250 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 69.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 69.2 |
| Others | 30.8 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 5.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 30.9 |
| SMALL-CAP | 30.4 |
| MID-CAP | 26.1 |
| MICRO-CAP | 6.2 |
| LARGE-CAP | 5.1 |
| NANO-CAP | 1.3 |
Stocks belong to which Index?
About 29% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 71 |
| RUSSELL 2000 | 29 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 41 stocks in it's portfolio. About 65.7% of the portfolio is in top 10 stocks. CRBP proved to be the most loss making stock for the portfolio. CNTA was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AKRO | akero therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALVR | allovir inc | 1.41 | 11,202,000 | 9,056,820 | added | 14.31 | ||
| ANNX | annexon inc | 0.37 | 400,000 | 2,368,000 | unchanged | 0.00 | ||
| ANTX | an2 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| APLS | apellis pharmaceuticals inc | 13.49 | 3,006,980 | 86,721,300 | added | 4.38 | ||
| AUTL | autolus therapeutics plc | 0.10 | 176,000 | 638,880 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics inc | 0.15 | 465,440 | 972,770 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc | 2.19 | 552,000 | 14,053,900 | reduced | -20.00 | ||
| BDTX | black diamond therapeutics i | 0.40 | 594,000 | 2,583,900 | new | |||
| CNTA | centessa pharmaceuticals plc | 5.00 | 2,012,050 | 32,172,700 | reduced | -14.2 | ||
| COGT | cogent biosciences inc | 2.19 | 1,305,000 | 14,094,000 | new | |||
| CRBP | corbus pharmaceuticals hldgs | 3.58 | 1,115,000 | 23,002,400 | added | 128 | ||
| CYBN | cybin inc | 0.68 | 489,596 | 4,352,510 | new | |||
| CYBN | cybin inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DYN | dyne therapeutics inc | 1.47 | 262,726 | 9,437,120 | reduced | -77.75 | ||
| ELEV | elevation oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EYPT | eyepoint pharmaceuticals inc | 1.36 | 1,093,500 | 8,737,090 | unchanged | 0.00 | ||
| FATE | fate therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GOSS | gossamer bio inc | 1.41 | 9,187,880 | 9,062,930 | unchanged | 0.00 | ||